Urolithin A, a novel natural compound to target PI3K/AKT/mTOR pathway in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy and is highly resistant to standard treatment regimens. Targeted therapies against KRAS, a mutation present in an overwhelming majority of PDAC cases, have been largely ineffective. However, inhibition of downstream components in th...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Mol Cancer Ther
Main Authors: Totiger, Tulasigeri M., Srinivasan, Supriya, Jala, Venkatakrishna R., Lamichhane, Purushottam, Dosch, Austin R., Gaidarski, Alexander A., Joshi, Chandrashekhar, Rangappa, Shobith, Castellanos, Jason, Vemula, Praveen Kumar, Chen, Xi, Kwon, Deukwoo, Kashikar, Nilesh, VanSaun, Michael, Merchant, Nipun B., Nagathihalli, Nagaraj S.
Format: Artigo
Jezik:Inglês
Izdano: 2018
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6363854/
https://ncbi.nlm.nih.gov/pubmed/30404927
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-18-0464
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki